Home/Filings/4/0001104659-25-004591
4//SEC Filing

Carvajal Alejandra 4

Accession 0001104659-25-004591

CIK 0001442836other

Filed

Jan 16, 7:00 PM ET

Accepted

Jan 17, 7:18 PM ET

Size

14.4 KB

Accession

0001104659-25-004591

Insider Transaction Report

Form 4
Period: 2025-01-15
Carvajal Alejandra
SVP, Chief Legal Officer
Transactions
  • Sale

    Common Stock

    2025-01-16$0.58/sh5,096$2,95678,296 total
  • Award

    Stock Option (Right to Buy)

    2025-01-15+243,750243,750 total
    Exercise: $0.64Exp: 2035-01-14Common Stock (243,750 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-01-1512,50037,500 total
    Common Stock (12,500 underlying)
  • Award

    Restricted Stock Unit

    2025-01-15+54,16754,167 total
    Common Stock (54,167 underlying)
  • Exercise/Conversion

    Common Stock

    2025-01-15+12,50083,392 total
Footnotes (7)
  • [F1]Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 15, 2024.
  • [F2]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
  • [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F4]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
  • [F5]25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years.
  • [F6]The option shall vest in equal quarterly installments over four years from the date of grant.
  • [F7]The RSUs shall vest in equal annual installments over four years from the date of grant.

Issuer

Mersana Therapeutics, Inc.

CIK 0001442836

Entity typeother

Related Parties

1
  • filerCIK 0001645755

Filing Metadata

Form type
4
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 7:18 PM ET
Size
14.4 KB